Shaping the Forefront of Cancer Care Together
Experience Brings Ease and Efficiency
As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care.
Biopharmaceutical Solutions
Our proven portfolio of high-quality comprehensive tests and our regulatory-ready dataset can accelerate clinical trial enrollment, inform trial design, or create new insights from your banked samples to discover biomarkers, identify resistance, or determine which patients could benefit from your therapy.
Our FoundationOne®CDx and FoundationOne®Liquid CDx tests have 60% of all CDx approvals for NGS testing in the United States and Japan – the most of any diagnostic company2 – and we have capabilities to develop our portfolio for the upcoming European Union In Vitro Diagnostics Regulation (EU IVDR).
We provide broad access to precision medicine around the world, with our tests available in more than 100 countries, and offer flexible solutions to accelerate your commercial launch, such as our alert service to provide timely, de-identified alerts on biomarker populations to support marketing and sales effectiveness.
Proven Leadership for Biopharma & Research Partners
>1M
Patient Reports Delivered Globally
60%
of all US CDx approvals for NGS testing*
>100K
Patients in Our Clinico-Genomic Database (CGDB)
1. Reichert et al. Annals of Oncology 2022. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study https://doi.org/10.1016/j.annonc.2022.09.163
2. Data on file, Foundation Medicine, Inc., data as of Nov. 18, 2022.
* Data on file, Foundation Medicine Inc., data as of Nov. 18, 2022.
Important Safety Information
Select
FoundationOne CDx
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com.
FoundationOne Liquid CDx
FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.